HSP70 Inducer Therapies for Neurodegeneration

Migration, Crosslink

📖

HSP70 Inducer Therapies for Neurodegeneration

active

wiki page Created: 2026-04-02T07:19:02 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-hsp70-inducer-therapie

📖 Wiki Page

therapeutic832 wordssynced 2026-04-02

HSP70 Inducer Therapies for Neurodegeneration

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">HSP70 Inducer Therapies for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Category</td>
<td>Disease-Modifying Therapy</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Hsp70 (HSPA1A, HSPA8), Hsp40 co-chaperones</td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, ALS, FTD</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Induce Hsp70 expression to enhance protein quality control and clearance of misfolded proteins</td>
</tr>
<tr>
<td class="label">Development Stage</td>
<td>Preclinical to Phase I</td>
</tr>
<tr>
<td class="label">Protein</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">Hsp70 (HSPA1A)</td>
<td>HSPA1A</td>
</tr>
<tr>
<td class="label">Hsc70 (HSPA8)</td>
<td>HSPA8</td>
</tr>
<tr>
<td class="label">Grp78/BiP</td>
<td>HSPA5</td>
</tr>
<tr>
<td class="label">mtHsp70 (Grp75)</td>
<td>HSPA9</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Arimoclomol</td>
<td>HSF1 co-activator</td>
</tr>
<tr>
<td class="label">Celastrol</td>
<td>HSF1 activator</td>
</tr>
<tr>
<td class="label">17-DMAG</td>
<td>Hsp90 inhibitor</td>
</tr>
<tr>
<td class="label">Geldanamycin derivatives</t

...

HSP70 Inducer Therapies for Neurodegeneration

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">HSP70 Inducer Therapies for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Category</td>
<td>Disease-Modifying Therapy</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Hsp70 (HSPA1A, HSPA8), Hsp40 co-chaperones</td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, ALS, FTD</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Induce Hsp70 expression to enhance protein quality control and clearance of misfolded proteins</td>
</tr>
<tr>
<td class="label">Development Stage</td>
<td>Preclinical to Phase I</td>
</tr>
<tr>
<td class="label">Protein</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">Hsp70 (HSPA1A)</td>
<td>HSPA1A</td>
</tr>
<tr>
<td class="label">Hsc70 (HSPA8)</td>
<td>HSPA8</td>
</tr>
<tr>
<td class="label">Grp78/BiP</td>
<td>HSPA5</td>
</tr>
<tr>
<td class="label">mtHsp70 (Grp75)</td>
<td>HSPA9</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Arimoclomol</td>
<td>HSF1 co-activator</td>
</tr>
<tr>
<td class="label">Celastrol</td>
<td>HSF1 activator</td>
</tr>
<tr>
<td class="label">17-DMAG</td>
<td>Hsp90 inhibitor</td>
</tr>
<tr>
<td class="label">Geldanamycin derivatives</td>
<td>Hsp90 inhibitor</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Target</td>
</tr>
<tr>
<td class="label">2-phenylethynesulfonamide (PES)</td>
<td>Hsp70</td>
</tr>
<tr>
<td class="label">YTL-HE-71</td>
<td>Hsp70</td>
</tr>
<tr>
<td class="label">HSF1A</td>
<td>HSF1</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Source</td>
</tr>
<tr>
<td class="label">Curcumin</td>
<td>Turmeric</td>
</tr>
<tr>
<td class="label">Resveratrol</td>
<td>Grapes</td>
</tr>
<tr>
<td class="label">Quercetin</td>
<td>Various fruits</td>
</tr>
</table>

Hsp70 Inducer Therapies For Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

HSP70 Inducer Therapies for Neurodegeneration [@kieran2004]

Overview

Heat shock protein 70 (Hsp70) is a major molecular chaperone essential for protein quality control. Hsp70 induction represents a therapeutic strategy to enhance the cell's ability to refold misfolded proteins and clear aggregates in neurodegenerative diseases.

Molecular Mechanism

Hsp70 Family Members

Hsp70 Functions in Neurodegeneration

Protein Folding: Assist proper folding of nascent polypeptides

Aggregate Disassembly: Disassemble protein aggregates

Proteasomal Degradation: Deliver misfolded proteins to [UPS](/cell-types/ubiquitin-proteasome-system)

Autophagic Clearance: Coordinate with [autophagy](/entities/autophagy) receptors

Synaptic Protection: Protect synapses from proteostatic stress

Therapeutic Induction Pathways

HSF1 Activation: Heat shock factor 1 induces Hsp70 transcription
Hsp90 Inhibition: Inhibition releases HSF1 to induce Hsp70
Proteostasis Regulators: Small molecules that enhance Hsp70 activity

Therapeutic Strategies

HSF1 Activators

Direct Hsp70 Modulators

Natural Compounds

Disease-Specific Applications

Alzheimer's Disease

Hsp70 inducers address:

[Aβ](/proteins/amyloid-beta) oligomerization and plaque formation
[Tau](/proteins/tau) hyperphosphorylation and aggregation
Synaptic protein dysfunction
Proteostasis network decline

Preclinical evidence:

Reduced [Aβ](/proteins/amyloid-beta) plaques in AD mouse models
Improved memory and cognition
Enhanced [tau](/proteins/tau) clearance

Parkinson's Disease

Target:

[α-Synuclein](/proteins/alpha-synuclein) aggregation
Mitochondrial protein quality control
Dopaminergic neuron survival

Studies show:

Reduced α-synuclein inclusions
Protected dopaminergic [neurons](/entities/neurons)
Improved motor function in models

Huntington's Disease

Benefits:

Mutant [huntingtin](/proteins/huntingtin-protein) (mHTT) clearance
Improved neuronal survival
Motor function preservation

Amyotrophic Lateral SALS

Arimoclomol (BRL-5906):

Phase III trial in SOD1-ALS
Failed to meet primary endpoint
Ongoing studies in other subtypes

Clinical Evidence

Arimoclomol

Phase II trial: Safety, tolerability, biomarker modulation
Phase III trial (HEALEY-ALS): Did not meet primary endpoint
Orphan drug designation (FDA/EU)
Ongoing studies in sporadic ALS

Combination Approaches

Hsp70 + Hsp90 inhibitors: Sequential treatment
Hsp70 + autophagy enhancers: Synergistic clearance
Hsp70 + proteasome modulators: Enhanced degradation

Adverse Effects and Challenges

Potential Side Effects

Heat shock response side effects
Proteostasis adaptation
Potential for protein overload
Off-target effects

Challenges

Achieving sufficient brain penetration
Balancing chaperone induction vs. stress response
Biomarker development for target engagement
Long-term treatment effects

Research Directions

Next-generation HSF1 activators
Brain-penetrant Hsp70 modulators
Combination therapy optimization
Biomarker development
Gene therapy approaches (HSPA1A delivery)

External Links

[Arimoclomol Clinical Trials - ClinicalTrials.gov](https://clinicaltrials.gov/)
[HSF1 and Neurodegeneration - Nature Reviews Drug Discovery](https://pubmed.ncbi.nlm.nih.gov/)
[Hsp70 in Alzheimer's - Acta Neuropathologica](https://pubmed.ncbi.nlm.nih.gov/)
[Protein Quality Control - Cold Spring Harbor Perspectives](https://pubmed.ncbi.nlm.nih.gov/)

Background

The study of Hsp70 Inducer Therapies For Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

References

[Neef DW, et al, A small molecule inhibitor of inducible heat shock protein 70 (2010)](https://pubmed.ncbi.nlm.nih.gov/20167533/)

[Kieran D, et al, Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice (2004)](https://pubmed.ncbi.nlm.nih.gov/15578093/)

[Calamini B, et al, Small-molecule proteostasis regulators for treatment of human disease (2011)](https://pubmed.ncbi.nlm.nih.gov/21627986/)

[Balch WE, et al, Adapting proteostasis for disease intervention (2008)](https://pubmed.ncbi.nlm.nih.gov/18323444/)

[Chen Y, et al, Heat shock protein 70 in neurodegenerative diseases (2011)](https://pubmed.ncbi.nlm.nih.gov/22108815/)

[Muchowski PJ, et al, The Hsp70 and Hsp40 molecular chaperones enable disassemblase activity (2000)](https://pubmed.ncbi.nlm.nih.gov/10639140/)

[Procaccia V, et al, HSF1 activation by small molecules (2020)](https://pubmed.ncbi.nlm.nih.gov/32065301/)

[Broadley SA, et al, Hsp70 and neurodegeneration (2021)](https://pubmed.ncbi.nlm.nih.gov/33848542/)

📖 View canonical wiki page →

Related Entities

therapeutics-hsp70-inducer-therapies-neurodegeneration

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-hsp70-inducer-therapies-neurodegeneration
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-f168778412ee
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-hsp70-inducer-therapies-neurodegeneration'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

548

Outgoing

714

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

HSP70 Inducer Therapies for Neurodegeneration

HSP70 Inducer Therapies for Neurodegeneration

Introduction

HSP70 Inducer Therapies for Neurodegeneration

Introduction

Overview

Molecular Mechanism

Hsp70 Family Members

Hsp70 Functions in Neurodegeneration

Therapeutic Induction Pathways

Therapeutic Strategies

HSF1 Activators

Direct Hsp70 Modulators

Natural Compounds

Disease-Specific Applications

Alzheimer's Disease

Parkinson's Disease

Huntington's Disease

Amyotrophic Lateral SALS

Clinical Evidence

Arimoclomol

Combination Approaches

Adverse Effects and Challenges

Potential Side Effects

Challenges

Research Directions

See Also

External Links

Background

References

💬 Discussion